Related references
Note: Only part of the references are listed.Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial
Elena Guerini-Rocco et al.
CLINICAL CANCER RESEARCH (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Alterations in Breast Cancer Biomarkers Following Neoadjuvant Therapy
Srivarshini Cherukupalli Mohan et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones
Swathi Karthikeyan et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
Dimitra Georgopoulou et al.
NATURE COMMUNICATIONS (2021)
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
Otto Metzger Filho et al.
CANCER DISCOVERY (2021)
PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications
Charlotte Levin Tykjaer Jorgensen et al.
CANCERS (2021)
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
Thomas Grinda et al.
NPJ BREAST CANCER (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy
Daniel J. Smit et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Caroline Boman et al.
CANCER TREATMENT REVIEWS (2021)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Aftimos et al.
CANCER DISCOVERY (2021)
Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases
Li Peng et al.
PATHOLOGY & ONCOLOGY RESEARCH (2021)
Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy
Luigi Rossi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
A. G. Waks et al.
ANNALS OF ONCOLOGY (2020)
Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software
Lieze Berben et al.
HISTOPATHOLOGY (2020)
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Nicholas C. Turner et al.
CLINICAL CANCER RESEARCH (2020)
Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer
Ming Fan et al.
NATURE COMMUNICATIONS (2020)
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Juliane Winkler et al.
NATURE COMMUNICATIONS (2020)
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study
Parisa Lotfinejad et al.
DIAGNOSTICS (2020)
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
Caterina Fumagalli et al.
BREAST CANCER RESEARCH (2020)
How the ageing microenvironment influences tumour progression
Mitchell Fane et al.
NATURE REVIEWS CANCER (2020)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Sibylle Loibl et al.
CLINICAL CANCER RESEARCH (2019)
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer
Marie Colombe Agahozo et al.
ENDOCRINE-RELATED CANCER (2019)
Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer
Junnan Xu et al.
ONCOLOGY LETTERS (2019)
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
Irene De Santo et al.
CANCERS (2019)
Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer
Ming Fan et al.
EUROPEAN RADIOLOGY (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
Ming Li et al.
BMC CANCER (2018)
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
Norman Sachs et al.
CELL (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren et al.
CELL (2018)
Mismatch Repair Protein Loss as a Prognostic and Predictive Biomarker in Breast Cancers Regardless of Microsatellite Instability
Nicola Fusco et al.
JNCI CANCER SPECTRUM (2018)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
Radiomics: the bridge between medical imaging and personalized medicine
Philippe Lambin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers
Taigo Kato et al.
ONCOTARGET (2017)
Intratumoral heterogeneity and subclonal diversification of early breast cancer
Lucy R. Yates
BREAST (2017)
Tumor Heterogeneity in Breast Cancer
Gulisa Turashvili et al.
FRONTIERS IN MEDICINE (2017)
HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma
Yanjun Hou et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
Alejandra Bruna et al.
CELL (2016)
Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer
Rekha Gyanchandani et al.
CLINICAL CANCER RESEARCH (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity
Qing Zhong et al.
SCIENTIFIC REPORTS (2016)
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
Yan Mao et al.
PLOS ONE (2016)
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
Andreas Heindl et al.
LABORATORY INVESTIGATION (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates et al.
NATURE MEDICINE (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
Hee Jin Lee et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
Gaetano Aurilio et al.
EUROPEAN JOURNAL OF CANCER (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients
Yu-Feng Yang et al.
MEDICAL ONCOLOGY (2014)
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Hugo J. W. L. Aerts et al.
NATURE COMMUNICATIONS (2014)
Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Justin M. Balko et al.
CANCER DISCOVERY (2014)
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers
S. Lindsey Davis et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative
O. Brouckaert et al.
ANNALS OF ONCOLOGY (2013)
Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics
W. Onstenk et al.
CANCER TREATMENT REVIEWS (2013)
Liquid biopsy: monitoring cancer-genetics in the blood
Emily Crowley et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Single-Cell Genetic Analysis of Ductal Carcinoma in Situ and Invasive Breast Cancer Reveals Enormous Tumor Heterogeneity yet Conserved Genomic Imbalances and Gain of MYC during Progression
Kerstin Heselmeyer-Haddad et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Mutational Processes Molding the Genomes of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
The extracellular matrix: A dynamic niche in cancer progression
Pengfei Lu et al.
JOURNAL OF CELL BIOLOGY (2012)
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection
Lucia Hernandez et al.
JOURNAL OF PATHOLOGY (2012)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
Genetic heterogeneity and cancer drug resistance
Nicholas C. Turner et al.
LANCET ONCOLOGY (2012)
Evolution of the cancer genome
Lucy R. Yates et al.
NATURE REVIEWS GENETICS (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Tim Forshew et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Intra-tumour heterogeneity: a looking glass for cancer?
Andriy Marusyk et al.
NATURE REVIEWS CANCER (2012)
Aligned Collagen Is a Prognostic Signature for Survival in Human Breast Carcinoma
Matthew W. Conklin et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype
Neill Patani et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
The Warrens and other pioneering clinician pathologists of the Massachusetts General Hospital during its early years: an appreciation on the 200th anniversary of the hospital founding
Robert H. Young et al.
MODERN PATHOLOGY (2011)
Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer
Ebru Sari et al.
MEDICAL ONCOLOGY (2011)
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
M. Gerlinger et al.
BRITISH JOURNAL OF CANCER (2010)
Immunohistochemically Determined Estrogen Receptor Phenotype Remains Stable in Recurrent and Metastatic Breast Cancer
Carmen Gomez-Fernandez et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients
Lisa K. Dunnwald et al.
BREAST CANCER RESEARCH (2007)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
HER2 expression in breast cancer primary tumours and corresponding metastases.: Original data and literature review
J Carlsson et al.
BRITISH JOURNAL OF CANCER (2004)
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
R Clarke et al.
ONCOGENE (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
